Disc MedicineIRON -0.30%34 PB Ratio is 3.89 as of Jun. 26, 2026. GuruFocus rates IRON with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,233 Biotechnology companies, Disc Medicine ranks worse than 62.45% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Disc Medicine's share price is $70.075. Disc Medicine's Book Value per Share for the quarter that ended in Mar. 2026 was $18.03. Hence, Disc Medicine's PB Ratio of today is 3.89.
The historical rank and industry rank for Disc Medicine's PB Ratio or its related term are showing as below:
IRON'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 3.97
Current: 3.89
During the past 6 years, Disc Medicine's highest PB Ratio was 3.97. The lowest was 0.00. And the median was 0.00.
IRON's PB Ratio is ranked worse than 62.45% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs IRON: 3.89
During the past 12 months, Disc Medicine's average Book Value Per Share Growth Rate was 31.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 24.40% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Disc Medicine was 24.40% per year. The lowest was 24.40% per year. And the median was 24.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Disc Medicine PB Ratio Related Terms
Disc Medicine PB Ratio Historical Data
* Premium members only.
The historical data trend for Disc Medicine's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Disc Medicine's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Disc Medicine PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Disc Medicine's PB Ratio distribution charts can be found below:
* The bar in red indicates where Disc Medicine's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Disc Medicine's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Disc Medicine (IRON) has a PB Ratio of 3.89 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Disc Medicine and its competitors. According to the industry distribution chart, Disc Medicine ranks #770 out of 1233 companies in the Biotechnology industry, placing it in the top 62.4%.
Is Disc Medicine's PB Ratio too high?
Disc Medicine's current PB Ratio is 3.89. The Biotechnology industry median PB Ratio is 2.80. Disc Medicine's value of 3.89 is 38.9% above this industry median. Based on the distribution chart, Disc Medicine ranks #770 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Disc Medicine has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Disc Medicine's PB Ratio compare to DFTX and ARQT?
According to the Biotechnology industry distribution chart, Disc Medicine ranks #770 out of 1233 companies for PB Ratio. This places Disc Medicine in the lower half of its industry. The industry median PB Ratio is 2.80. Disc Medicine's value of 3.89 is 38.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Disc Medicine's current PB Ratio of 3.89 is 38.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Disc Medicine and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Disc Medicine's current PB Ratio is 3.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disc Medicine stock overvalued right now?
Disc Medicine (IRON) has a current PB Ratio of 3.89. The current PB Ratio is 3.89 and 38.9% above the Biotechnology industry median of 2.80. Disc Medicine's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Disc Medicine (IRON), the current PB Ratio is 3.89 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
34GF Score
Get the complete analysis for IRON
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRON has been successfully added to your 
